The companies declined to disclose the amount of funding.
Quest retains an option to commercialize specific Correlogic diagnostics for particular disease states, the companies said. The company has also licensed Correlogic's OvaCheck for commercialization, the companies said.
OvaCheck was the subject of a February letter sent to Correlogic by Steve Gutman, director of the US Food and Drug Administration's Office of In Vitro Diagnostic Device Evaluation and Safety notifying the company that the diagnostic may be subject to the agency's premarket review requirements.
OvaCheck is now in validation testing, Correlogic said.
Correlogic is also developing a prostate cancer diagnostic with the